Zobrazeno 61 - 70
of 99
pro vyhledávání: '"Allison Berger"'
Autor:
Paul G. Richardson, Alessandra Di Bacco, Andrew Dorner, Allison Berger, Deborah Ricci, Pieter Sonneveld, Erik Koenig, Robert Z. Orlowski, Jeśus F.San Miguel, Hugues Bernard, Edward A. Stadtmauer, William L. Trepicchio, David I. Lichter, Helgi van de Velde, Sundar Jagannath, Matthew Schu, Kenneth C. Anderson, Stephen J. Blakemore, Nibedita Chattopadhyay, Dixie Lee Esseltine, George Mulligan, Joseph B. Bolen, Rachel Neuwirth, Bin Li, Sagar Lonial, James R. Berenson
Publikováno v:
Blood, 123(5), 632-639. American Society of Hematology
Various translocations and mutations have been identified in myeloma, and certain aberrations, such as t(4;14) and del17, are linked with disease prognosis. To investigate mutational prevalence in myeloma and associations between mutations and patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc7a06d9996ee11f17c51fcbb70b586
https://europepmc.org/articles/PMC4123425/
https://europepmc.org/articles/PMC4123425/
Autor:
Isere Kuiatse, Hua Wang, Nibedita Chattopadhyay, Robert Z. Orlowski, Saurabh Menon, Judy Qiuju Shi, Junling Zhuang, Hans C. Lee, Vaishali Shinde, Allison Berger, Marc L. Hyer, Anna Kreshock, Stephen Tirrell, Sakeena Syed, Jie Yu, Richard J. Jones, Fazal Shirazi
Publikováno v:
Blood. 128:3296-3296
Background: The ubiquitin-proteasome system (UPS) has been validated as a target in multiple myeloma (MM) through the success of proteasome inhibitors such as bortezomib, but drug resistance is an emerging challenge. Targeting some of the upstream co
Autor:
Lunyin Yu Yu, Dirk Huebner, Yuhong Zhang, Jie Yu, Stephen Tirrell, Dan He McDougall, Helgi van de Velde, Allison Berger, Sakeena Syed, Christopher Tremblay, Nibedita Chattopadhyay
Publikováno v:
Blood. 128:1842-1842
The ubiquitin-proteasome system (UPS) represents the primary mechanism by which cells degrade proteins. Proteasome inhibition results in accumulation of proteasome substrates, leading to cell cycle disruption, endoplasmic reticulum (ER) stress, activ
Autor:
Kristin E. Burke, Doug Bowman, Arijit Chakravarty, Mark D. Fleming, Jeffrey Ecsedy, A. A. McDonald, Vaishali Shinde, Stephen Tirrell, Stephen J. Blakemore, Allison Berger
Publikováno v:
Veterinary pathology. 51(1)
Immunohistochemistry-based biomarkers are commonly used to understand target inhibition in key cancer pathways in preclinical models and clinical studies. Automated slide-scanning and advanced high-throughput image analysis software technologies have
Publikováno v:
International Journal of Doctoral Studies; 2018, Vol. 13, p293-311, 19p
Autor:
Allison Berger, Darshan S. Sappal, Kenichi Iwai, Yuko Ishii, Neil F. Bence, Jennifer Duffy, Eric S. Lightcap, Jeffrey Ciavarri, Marc L. Hyer, Akihiro Ohashi, Jessica Huck, Judy Qiuju Shi, Tary Traore, Michael Milhollen, Claudia Rabino
Publikováno v:
Cancer Research. 76:3719-3719
Radiation therapy, as a primary therapy or as a combination partner, is used in half of all worldwide cancer treatments. Research is ongoing to identify agents which potentiate the effects of ionizing radiation (IR) in tumor cells. Because IR causes
Autor:
Stephen E. Spurgeon, Christopher George Danes, Claire Godbersen, Allison Berger, Cody Paiva, Alexey V. Danilov
Publikováno v:
Blood. 126:3994-3994
Background Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the U.S. DLBCL can be subdivided into the activated B-cell-like (ABC) and germinal center B-cell-like (GCB) subgroups on the basis of gene expressi
Autor:
Xiaozhen J. Liu, Eric S. Lightcap, Allison Berger, Khristofer Garcia, Jonathan L. Blank, Erik Koenig, David C. Bouck, Mike Kuranda, Hugues Bernard
Publikováno v:
Molecular Cancer Therapeutics. 14:C55-C55
Platinum-based therapies, both cisplatin and carboplatin, are utilized as part of first-line standard of care regimens for advanced non-small cell lung cancer (NSCLC), but overall response rate and overall survival remain limited, with a 5-year survi
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Publikováno v:
Cell Death & Disease
Microenvironment-mediated upregulation of the B-cell receptor (BCR) and nuclear factor-κB (NF-κB) signaling in CLL cells resident in the lymph node and bone marrow promotes apoptosis evasion and clonal expansion. We recently reported that MLN4924 (